单克隆丙种球蛋白病患者中意义未明单克隆丙种球蛋白病样表型的定义及临床意义
研究基于548例MGUS和2011例活动性MM患者骨髓浆细胞及克隆性浆细胞百分比,用流式细胞术开发识别MGUS样表型的算法,并在488例冒烟型MM、3870例活动性MM和211例AL淀粉样变性患者中验证。冒烟型MM中MGUS样表型2年进展率分别为4.5%和0%(两个独立系列);活动性MM中该表型为独立预后因素(PFS HR 0.49,P=0.001;OS HR 0.56,P=0.039)。
要点
- 基于骨髓总浆细胞及克隆性浆细胞百分比开发开放获取算法识别MGUS样表型。
- 冒烟型MM中MGUS样表型2年进展率分别为4.5%和0%(两个独立系列)。
- 活动性MM中MGUS样表型为PFS和OS的独立预后因素。
核心结论
- 研究开发了开放获取算法用于识别具有不同临床结局的MGUS样患者。
- 作者认为该表型分类可成为MM和AL淀粉样变性诊断检查的一部分。
研究设计与样本
- 算法基于诊断时流式细胞术测定的骨髓总浆细胞百分比及骨髓浆细胞区室中克隆性浆细胞百分比,在548例MGUS和2011例活动性MM患者中开发。
- 算法在488例冒烟型MM、3870例活动性MM和211例AL淀粉样变性患者中检验并验证。
主要发现
- 冒烟型MM中MGUS样表型患者疾病进展率显著较低,两个独立系列2年进展率分别为4.5%和0%。
- 冒烟型MM中MGUS样表型患者治疗与观察相比至进展时间无统计学显著差异。
- 活动性新诊断MM多因素分析中,MGUS样表型对PFS保留独立预后价值(HR 0.49,P=0.001),对OS亦保留独立预后价值(HR 0.56,P=0.039),与ISS、乳酸脱氢酶、细胞遗传学风险、移植资格和完全缓解状态一起分析。
- 活动性MM中符合移植条件的MGUS样表型患者5年PFS率和OS率分别为79%和96%。
- 该亚组中,完全缓解和可测量残留病灶状态不同的患者PFS和OS无差异。
临床怎么用
- 作者认为该表型分类可成为MM和AL淀粉样变性诊断检查的一部分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present with a monoclonal gammopathy of undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup are not standardized and its clinical significance is not properly validated. PATIENTS AND METHODS: An algorithm to identify patients having MGUS-like phenotype was developed on the basis of the percentages of total bone marrow (BM) plasma cells (PC) and of clonal PC within the BM PC compartment, determined at diagnosis using flow cytometry in 548 patients with MGUS and 2,011 patients with active MM. The clinical significance of the algorithm was tested and validated in 488 patients with smoldering MM, 3,870 patients with active MM and 211 patients with AL amyloidosis. RESULTS: Patients with smoldering MM with MGUS-like phenotype showed significantly lower rates of disease progression (4.5% and 0% at 2 years in two independent series). There were no statistically significant differences in time to progression between treatment versus observation in these patients. In active newly diagnosed MM, MGUS-like phenotype retained independent prognostic value in multivariate analyses of progression-free survival (PFS; hazard ratio [HR], 0.49; P = .001) and overall survival (OS; HR, 0.56; P = .039), together with International Staging System, lactate dehydrogenase, cytogenetic risk, transplant eligibility, and complete remission status. Transplant-eligible patients with active MM with MGUS-like phenotype showed PFS and OS rates at 5 years of 79% and 96%, respectively. In this subgroup, there were no differences in PFS and OS according to complete remission and measurable residual disease status. Application of the algorithm in two independent series of patients with AL predicted for different survival. CONCLUSION: We developed an open-access algorithm for the identification of MGUS-like patients with distinct clinical outcomes. This phenotypic classification could become part of the diagnostic workup of MM and AL amyloidosis.
引用
- Burgos L, Tamariz-Amador LE, Puig N, et al. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies. J Clin Oncol. 2023. PMID: 36930848. doi:10.1200/JCO.22.01916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。